In this issue of the Archives, Heinemann1 reports the results of long-term intravitreal ganciclovir injection therapy for patients with acquired immunodeficiency syndrome (AIDS) with cytomegalovirus (CMV) retinitis. As the AIDS epidemic has grown to affect all population centers in this country, ophthalmologists have more frequently been encountering and treating patients with CMV retinitis. Recently the Food and Drug Administration approved the use of intravenous ganciclovir after reviewing a large body of reports, largely by ophthalmologists, of the efficacy of this drug in patients with AIDS with CMV retinitis. The enthusiasm for ganciclovir stems not from an extraordinarily high clinical success rate or ease of use but rather from the inexorable progression of untreated CMV retinitis, with resulting blindness.2-4 Clinicians using ganciclovir therapy are confronted with many serious difficulties, including frequent bone marrow toxicity most commonly manifested by neutropenia (absolute neutrophil count <500 to 1000). Other difficulties include the
Freeman WR. Intraocular Antiviral Therapy. Arch Ophthalmol. 1989;107(12):1737–1739. doi:10.1001/archopht.1989.01070020819020
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: